Abstract
The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer. Seventy-eight consecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentially curative surgery were retrospectively reviewed. The SUVmax was significantly higher in the patients with recurrent than with non-recurrent adenocarcinoma (p<0.01). However, among the patients with squamous cell carcinoma, there were no differences with or without recurrence (p=0.69). Multivariate analysis indicated that the SUVmax of adenocarcinoma lesions was a significant predictor of disease-free survival (p=0.04). In addition, an SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IB or more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p<0.01). SUVmax is a useful predictor of disease-free survival in patients with resected adenocarcinoma, but not squamous cell carcinoma. Patients with adenocarcinoma exhibiting an SUVmax above 6.19 are candidates for more intensive adjuvant therapy.
Highlights
Materials and MethodsRecently, [18F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) has become a valuable tool for evaluating the clinical stage, response to therapy (Mac Manus et al, 2003; Hoekstra et al, 2005; Al-Jahdali, et al, 2012; Ding et al, 2012), metastatic potential (Kaya et al, 2008; Zhu et al, 2013) and diagnosis of recurrence (Hicks et al, 2001) in patients with non-small cell lung cancer (NSCLC)
The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer
Due to the small number of patients with other histologic types, only those with adenocarcinoma or squamous cell carcinoma were enrolled in the analysis
Summary
Materials and MethodsRecently, [18F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) has become a valuable tool for evaluating the clinical stage (de Geus-Oei et al, 2007; Al-Jahdali et al, 2012; Liu et al, 2012; Mutlu, et al, 2013), response to therapy (Mac Manus et al, 2003; Hoekstra et al, 2005; Al-Jahdali, et al, 2012; Ding et al, 2012), metastatic potential (Kaya et al, 2008; Zhu et al, 2013) and diagnosis of recurrence (Hicks et al, 2001) in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer. Materials and Methods: Seventy-eight consecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentially curative surgery were retrospectively reviewed. An SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IB or more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
